This study aimed to systematically evaluate the efficacy and safety of combination therapies with immune checkpoint inhibitors (ICIs) in patients with driver gene-negative non-small cell lung cancer (NSCLC) and liver metastases. These patients typically have poor prognosis and limited responses to immunotherapy. This study synthesized existing literature by conducting a network meta-analysis to determine the most effective first-line ICI combination regimen to guide clinical treatment decisions.

We aimed to explore the prognostic role of circulating DNA-related markers to improve clinical decision-making in patients with lung malignancies.

We aimed to evaluate the diagnostic performance of deep learning (DL)-based radiomics models for the noninvasive prediction of isocitrate dehydrogenase (IDH) mutation and 1p/19q co-deletion status in glioma patients using MRI sequences, and to identify methodological factors influencing accuracy and generalizability.

Poly (ADP-ribose) polymerase inhibitors (PARPi) have become a key treatment for ovarian cancer, particularly in patients with BRCA mutations or homologous recombination deficiency (HRD).

Metastatic uveal melanoma (mUM) is a rare disease associated with poor prognosis and limited therapeutic options. Recent studies showed that detecting ctDNA is feasible and can aid treatment decisions for patients with mUM. We systematically searched PubMed, EMBASE, and Cochrane databases for eligible studies published up to May 2025 that included patients with mUM and reported data on the association between ctDNA and survival outcomes (OS and PFS). Statistical analyses were performed using Review Manager 5.4 software. Of the initial 450 records, seven studies met eligibility, including 518 patients with mUM. At baseline, ctDNA positivity was associated with significantly worse PFS (HR 2.34; 95% CI 1.56-3.51; p < 0.01; I2 = 0%) and OS (HR 3.32; 95% CI 2.09-5.29; p < 0.01; I2 = 48%). In patients treated with tebentafusp, ctDNA clearance was associated with superior OS (HR 0.19; 95% CI 0.07-0.49; p < 0.01; I2 = 46%) and any decrease in ctDNA was associated with better OS (HR 0.42; 95% CI 0.22-0.80; p < 0.01; I2 = 0%). This meta-analysis underscores ctDNA as a potential predictor of worse survival in patients with mUM, highlighting its potential to refine risk stratification and guide treatment strategies. Trial Registration: International Prospective Register of Systematic Reviews (PROSPERO): CRD42025638076.

The skin microbiome has been linked to the etiology and progression of skin cancer, but the causal relationship remains unclear. This study employs two-sample Mendelian randomization (TSMR) and meta-analysis techniques to elucidate the putative genetic causal relationships between skin microbiota and skin cancer. Genetic variant data for the skin microbiome and skin cancer, drawn from large-scale genome-wide association studies, were extracted from European populations. TSMR analysis, heterogeneity tests, horizontal pleiotropy assessments, sensitivity analysis, and directional tests were conducted, followed by a meta-analysis to enhance the reliability of the findings. The TSMR and meta-analysis results indicate a significant association between the Proteobacteria phylum, including Gammaproteobacteria, and an increased risk of melanoma. Conversely, the Staphylococcus genus is significantly associated with a reduced risk of melanoma. Additionally, the Bacteroidetes phylum exhibits a statistically significant association with an elevated risk of basal cell carcinoma. This study furnishes genetic evidence substantiating the causal nexus between the skin microbiome and skin cancer. Further research is warranted to elucidate the underlying mechanisms and explore skin microbiome-centric prophylactic and therapeutic strategies for skin cancer.

Type 1 Diabetes Mellitus (T1DM) is related to increased Polycystic Ovary Syndrome (PCOS) prevalence in women. However, the molecular mechanisms have not been fully elucidated.

Most studies suggest that NOTCH1 alterations are associated with prognosis in adenoid cystic carcinoma (ACC), but findings remain fragmented. We conducted an integrative analysis to evaluate the prognostic value of NOTCH1-related biomarkers in ACC.

To synthetically evaluate the diagnostic performance of circulating tumor DNA (ctDNA) methylation for colorectal cancer (CRC).

Gastrointestinal cancers (GICs), encompassing malignancies of the esophagus, stomach, and colorectal regions, are among the most prevalent cancers worldwide. Given the inconsistent and heterogeneous findings across studies, this meta-analysis aims to comprehensively assess the association between vitamin D receptor (VDR) gene polymorphisms and the risk of GICs.

Previous observational studies have indicated that omega-3 may reduce the risk of various cancers. However, the relationship between omega-3 and the incidence of multiple myeloma (MM) remains unclear. Therefore, we conducted a systematic Mendelian randomization (MR) analysis to investigate the causal relationship between omega-3 and the risk of developing MM, while also exploring the potential mediating role of plasma lipids in this association. First, we conducted a two-sample MR study with MM using the omega-3 GWAS data from Richardson TG. We then repeated the validation with the other three omega-3 GWAS data and performed a meta-analysis of the MR results for a total of four omega-3 data. In the second step, we used multivariate Mendelian randomization (MVMR) analyses to adjust for the effects of confounders and explore the direct causal effects of omega-3 with MM. In the third step, we employed a two-step MR to investigate the potential mediating roles of 179 plasma lipids in the association between omega-3 and the risk of MM. Multiple sensitivity analyses were used to assess the robustness of the results. A two-sample MR analysis found that omega-3 can reduce the risk of MM (OR = 0.80, 95% CI 0.69-0.94; P = 0.005). In subsequent validation, omega-3 data from both Kettunen J and Davyson E yielded similar results. However, data from Zhang S indicated that omega-3 was not associated with MM risk. Ultimately, the meta-analysis results demonstrated that omega-3 can lower the risk of MM (OR = 0.80, 95% CI 0.72-0.88; P < 0.001). Furthermore, MVMR analysis, after adjusting for relevant risk factors such as obesity and type 2 diabetes, confirmed that omega-3 still reduces the risk of MM. Finally, two-step MR identified phosphatidylcholine (18:2_20:4) as a potential mediator of the causal relationship between omega-3 and MM. Various sensitivity analyses validated the robustness of these findings. Our study suggests that omega-3 may reduce the incidence risk of MM by increasing the levels of phosphatidylcholine (18:2_20:4). We hope that these findings will provide new insights for the prevention and treatment of MM.

Pancreatic cancer is a highly lethal malignancy, ranking tenth in incidence among all cancers and standing as the fourth leading cause of cancer-related mortality worldwide. This systematic review and meta-analysis evaluated the diagnostic performance of exosomal biomarkers for detecting pancreatic ductal adenocarcinoma (PDAC). A total of 1,666 records were identified through comprehensive searches in Scopus, Web of Science, and PubMed. After removing duplicates and screening titles, abstracts, and full texts, 15 studies comprising 1,961 individuals (971 PDAC patients and 990 controls) were included. The quality of studies was assessed using the QUADAS-2 tool, revealing potential biases mainly in patient selection and index test domains. Three biomarker categories were analyzed: exosomal microRNAs (exomiRs), cancer antigen 19-9 (CA 19-9), and glypican-1 (GPC1). ExomiRs demonstrated the highest pooled sensitivity (0.86; 95 % CI: 0.80-0.90) and lowest negative likelihood ratio (0.16; 95 % CI: 0.11-0.24), while CA 19-9 showed the highest specificity (0.91; 95 % CI: 0.84-0.95) and positive likelihood ratio (8.5; 95 % CI: 4.4-16.4). ExomiRs also had the highest diagnostic odds ratio (DOR = 35.4; 95 % CI: 18.7-67.0) and area under the SROC curve (AUC = 0.92; 95 % CI: 0.89-0.94), indicating superior diagnostic performance compared to CA 19-9 and GPC1 (AUC = 0.88 and 0.78, respectively). GPC1 consistently showed lower diagnostic metrics across all analyses. Deeks' funnel plot suggested no publication bias for CA 19-9 and GPC1, but indicated potential bias for exomiRs (P = 0.01). Overall, exomiRs appear to be promising non-invasive biomarkers for the early detection of PDAC, outperforming traditional and other exosome-based markers in diagnostic accuracy.

Breast cancer is one of the most common malignancies worldwide with notable geographic variation in incidence and mortality. Its risk is shaped by both environmental and genetic factors. Among the genetic contributors, ESR1 intronic polymorphisms such as XbaI and PvuII have been associated with breast cancer susceptibility, though results across populations remain inconsistent.

We still do not know the exact cause of bladder cancer (BC).

The prognostic significance of BRCA1/2 mutation and RB1 alteration (Alt) in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer (BC) treated with endocrine therapy (ET) ± cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) remains unresolved. This meta-analysis aimed to define their influence on therapy outcomes in the early and metastatic stages.

The heterogeneous nature of c-MET overexpression in gastric cancer (GC) leads to a lack of consensus on its prognostic significance.

High expression levels of cluster of differentiation 47 (CD47) have been recognized as poor survival in several different cancers. Nevertheless, the significance of CD47 in patients with solid tumors remains controversial.

Adenoid cystic carcinoma (AdCC) is a rare, aggressive salivary gland malignancy with a poor prognosis due to metastasis and local recurrence. Although hypoxia-inducible factors-1/2α (HIF-1/2α) play crucial roles in AdCC, their pleiotropic effects remain poorly understood. This systematic review and meta-analysis evaluates the impact of HIF-1/2α in AdCC progression.

BackgroundCircular (circ)RNAs are essential regulators in cancer development and progression. CircPVT1, derived from exon 2 (410 nucleotides) of PVT1 gene located at 8q24, has been widely recognized as an oncogenic circRNA frequently upregulated in various human cancers. This study aimed to assess the diagnostic accuracy of circPVT1 for human cancers.MethodsArticles published up to July 2024 were searched across four databases (PubMed, EMBASE, Web of Science, and Cochrane databases). A meta-analysis was conducted under a random effects model and the diagnostic performance was evaluated using receiver operator characteristic curve analysis. Subgroup analysis of circPVT1 in different cancer types and tissues was performed.ResultsOverall, 12 studies (1246 patients) were included for diagnostic outcome synthesis. The pooled sensitivity was 0.83 (95% CI, 0.77-0.88) and specificity of 0.80 (95% CI, 0.73-0.87), with an area under the receiver operator characteristic curve of 0.89 (95% CI, 0.86-0.91), highlighting the robust diagnostic value of circPVT1. Multiple studies have revealed that circPVT1 functions as a micro RNA sequester to modulate downstream gene expression, affecting various malignant behaviors in cancers.ConclusionThis study enhances our understanding of the role and mechanism of circPVT1 in human cancers and supports its potential as a promising diagnostic biomarker for various cancer types.

Hepatocellular carcinoma (HCC) is one of the most prevalent and inflammation-associated cancers. The potential prognostic value of calcyclin-binding protein (CACYBP) in HCC remains unclear. We aimed to perform meta-analysis to clarify the association of CACYBP expression with prognosis.